Sionna Therapeutics, Inc. (SION)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Michael Cloonan M.B.A.
|
President, CEO & Director | 1.03M | -- | 1971 |
|
Ms. Elena H. Ridloff C.F.A.
|
CFO & Chief Business Officer | 771.6k | -- | 1980 |
|
Dr. Greg Hurlbut Ph.D.
|
Co-Founder & Senior VP of Discovery Research | -- | -- | -- |
|
Dr. Mark Munson Ph.D.
|
Co-founder | -- | -- | -- |
|
Mr. Andy Chu
|
Vice President of Information & Technology | -- | -- | -- |
|
Juliet Labadorf
|
Senior Director of Investor Relations & Corporate Development | -- | -- | -- |
|
Ms. Jennifer Fitzpatrick J.D.
|
Chief Legal Officer & Head of Program Management | -- | -- | 1977 |
|
Ms. Roxanne McGrath
|
Vice President of Head of Human Resources | -- | -- | -- |
|
Dr. Charlotte McKee M.D.
|
Chief Medical Officer & Head of Research and Development | 647.92k | -- | 1965 |
|
Ms. Mara Furlow M.S.
|
Senior Vice President of Global Regulatory Affairs & Quality | -- | -- | -- |
Sionna Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 59
Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Sionna Therapeutics, Inc. Earnings Date
